| Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States A Dasari, C Shen, D Halperin, B Zhao, S Zhou, Y Xu, T Shih, JC Yao JAMA oncology 3 (10), 1335-1342, 2017 | 2995 | 2017 |
| Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer S Kopetz, J Desai, E Chan, JR Hecht, PJ O'Dwyer, D Maru, V Morris, ... Journal of clinical oncology 33 (34), 4032, 2015 | 739 | 2015 |
| Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018 JM Loree, S Anand, A Dasari, JM Unger, A Gothwal, LM Ellis, ... JAMA oncology 5 (10), e191870-e191870, 2019 | 421 | 2019 |
| Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study DM Halperin, C Shen, A Dasari, Y Xu, Y Chu, S Zhou, YCT Shih, JC Yao The Lancet Oncology 18 (4), 525-534, 2017 | 364 | 2017 |
| Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes JM Loree, AAL Pereira, M Lam, AN Willauer, K Raghav, A Dasari, ... Clinical Cancer Research 24 (5), 1062-1072, 2018 | 323 | 2018 |
| Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment MP Morelli, MJ Overman, A Dasari, SMA Kazmi, T Mazard, E Vilar, ... Annals of Oncology 26 (4), 731-736, 2015 | 280 | 2015 |
| Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors AW Tolcher, WA Messersmith, SM Mikulski, KP Papadopoulos, EL Kwak, ... Journal of clinical oncology 30 (19), 2348, 2012 | 273 | 2012 |
| ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper A Dasari, VK Morris, CJ Allegra, C Atreya, AB Benson III, P Boland, ... Nature reviews Clinical oncology 17 (12), 757-770, 2020 | 272 | 2020 |
| Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1–mediated activation of two GC-rich … A Dasari, JN Bartholomew, D Volonte, F Galbiati Cancer research 66 (22), 10805-10814, 2006 | 253 | 2006 |
| Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases A Dasari, K Mehta, LA Byers, H Sorbye, JC Yao Cancer 124 (4), 807-815, 2018 | 223 | 2018 |
| A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014 WA Messersmith, GI Shapiro, JM Cleary, A Jimeno, A Dasari, B Huang, ... Clinical Cancer Research 21 (1), 60-67, 2015 | 223 | 2015 |
| Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives M Aapro, P Bossi, A Dasari, L Fallowfield, P Gascón, M Geller, K Jordan, ... Supportive care in cancer 28, 4589-4612, 2020 | 212 | 2020 |
| Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge CM Parseghian, JM Loree, VK Morris, X Liu, KK Clifton, S Napolitano, ... Annals of Oncology 30 (2), 243-249, 2019 | 199 | 2019 |
| Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? S Das, A Dasari Current oncology reports 23, 1-7, 2021 | 194 | 2021 |
| Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer V Morris, MJ Overman, ZQ Jiang, C Garrett, S Agarwal, C Eng, B Kee, ... Clinical colorectal cancer 13 (3), 164-171, 2014 | 144 | 2014 |
| A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma A De Jesus-Acosta, D Laheru, A Maitra, J Arcaroli, MA Rudek, A Dasari, ... Investigational new drugs 32, 739-745, 2014 | 108 | 2014 |
| Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials N Vijayvergia, A Dasari, M Deng, S Litwin, T Al-Toubah, RK Alpaugh, ... British journal of cancer 122 (9), 1309-1314, 2020 | 99 | 2020 |
| Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer AM Sarshekeh, S Advani, MJ Overman, G Manyam, BK Kee, ... PLoS One 12 (3), e0173345, 2017 | 95 | 2017 |
| Who should get lateral pelvic lymph node dissection after neoadjuvant chemoradiation? S Malakorn, Y Yang, BK Bednarski, H Kaur, YN You, EB Holliday, ... Diseases of the Colon & Rectum 62 (10), 1158-1166, 2019 | 91 | 2019 |
| Representativeness of Black patients in cancer clinical trials sponsored by the National Cancer Institute compared with pharmaceutical companies JM Unger, DL Hershman, RU Osarogiagbon, A Gothwal, S Anand, ... JNCI Cancer Spectrum 4 (4), pkaa034, 2020 | 77 | 2020 |
